Company cofounder to focus on use of synthetic intelligence and machine studying purposes for precision drugs in neurology
BOSTON, Jan. 24, 2023 /PRNewswire/ — Beacon Biosignals CEO and co-founder Jacob Donoghue, MD, Ph.D., shall be talking at the Precision Medicine World Conference (PMWC) 2023 being held in Silicon Valley from Jan. 25-27, the corporate introduced immediately.
The PMWC is the foremost precision drugs convention, bringing collectively greater than 2,500 acknowledged leaders, prime international researchers, medical professionals and innovators in an effort to speed up the event and unfold of precision drugs. It supplies a discussion board for the change of details about the newest advances in expertise, medical implementation, analysis, and in all points associated to the regulatory and reimbursement sectors.
Dr. Donoghue shall be a part of a panel session titled “AI/ML Applications for Patient Outcomes Prediction and Clinical Support” on Friday, Jan. 27, from 1 to 2 p.m. at the Santa Clara Convention Center in Santa Clara, Calif. This session is a part of Track 2 (AI & Data Sciences in Drug Discovery & Clinical Research) on Day 3 of the annual convention.
The panel shall be moderated by Alex Sherman, a principal affiliate in Neurology at Harvard Medical School and director of the Center for Innovation and Bioinformatics at the Neurological Clinical Research Institute at Massachusetts General Hospital (MGH). In addition to Dr. Donoghue, confirmed panelists embrace:
Indu Navar, EverythingALS
Nuray Yurt, Novartis Oncology
Marie Abele Bind, MGH/Harvard Medical School
Dr. Donoghue accomplished his medical diploma from the Health Sciences & Technology program at Harvard Medical School and his Ph.D. in neuroscience from MIT, the place his analysis centered on computational neurophysiology and the results of neuroactive compounds on mind community exercise. He co-founded Beacon Biosignals in 2019.
Dr. Donoghue will focus on Beacon’s progress utilizing machine studying to analyze epileptiform burden and sleep endpoints derived from electroencephalogram (EEG) recordings. Stratifying sufferers primarily based on these insights supplies a extra detailed understanding of a affected person’s situation, and may lead to extra focused and efficient therapy plans.
The world’s main computational neurodiagnostics firm, Beacon harnesses machine studying that unlocks the facility of EEG information to advance precision medicines for neurologic and psychiatric problems.
About Beacon Biosignals Beacon’s machine studying platform for EEG allows and accelerates new remedies that remodel the lives of sufferers with neurological, psychiatric or sleep problems. Through novel machine studying algorithms, giant medical datasets, and advances in software program engineering, Beacon Biosignals empowers biopharma corporations with unparalleled instruments for efficacy monitoring, affected person stratification, and medical trial endpoints from mind information. For extra info, go to https://beacon.bio/. For careers, go to https://beacon.bio/careers; for partnership inquiries, go to https://beacon.bio/contact. Follow us on Twitter (@Biosignals) or LinkedIn (https://www.linkedin.com/company/beacon-biosignals).
MEDIA CONTACTMegan MoriartyAmendola Communications for Beacon Biosignals913.515.7530[email protected]
SOURCE Beacon Biosignals